Regeneron UK Limited has announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo (cemiplimab) for use on ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

The approval means that Libtayo is now the first immunotherapy approved in Europe to treat advanced cervical cancer, regardless of PD-L1 expression or tumour histology. The fourth leading cause of ...

Sanofi and Regeneron’s checkpoint inhibitor Libtayo has become the first immunotherapy to improve survival when used as a second-line therapy in cervical cancer, setting up regulatory filings ...

A new University of Kentucky Markey Cancer Center study provides important insights for future clinical trials in treating ...

A mother of three was blindsided by a cervical cancer diagnosis just days before her 30th birthday — despite experiencing ...

Cervical cancer is one of the leading cancers that affects millions of women in India and worldwide; however, one needs to understand that cervical cancer can be prevented or treated if it is ...

Cervical cancer is one of the most common cancers, and it develops due to abnormal cell growth in the cervix, triggered by persistent infection with the human papillomavirus (HPV). The common ...

Dr. Ritu Salani discusses how patients with cervical cancer can advocate for their health and collaborate with their medical team to ensure the best care.